Meharry-Vanderbilt partnership aims to address racial disparity in cancer outcomes

October 27, 1999

NASHVILLE, Tenn. (October 28, 1999) - The National Cancer Institute has awarded more than $1 million to support a new partnership between Meharry Medical College and the Vanderbilt-Ingram Cancer Center.

Through this partnership, Meharry and the Vanderbilt-Ingram Cancer Center will collaborate on research and patient care initiatives that ultimately are hoped to help close the gap between blacks and whites in cancer incidence and deaths.

The work will be coordinated through an alliance, announced earlier this year, between Meharry and Vanderbilt Medical Center to enhance educational, scientific and clinical programs at and between both institutions.

"It is of great concern that, at the turn of the 21st Century, African-Americans remain more likely to develop cancer - and to die from it - than white Americans," said Dr. John E. Maupin, president of Meharry Medical College and member of the Vanderbilt-Ingram Cancer Center Board of Overseers.

"The key is to better understand precisely why this disparity exists. We have ideas and can make intelligent guesses, but we need to do the rigorous scientific studies to answer those questions. Through this partnership, we will be better positioned to find those answers together than either institution could be alone."

Dr. Harry R. Jacobson, vice chancellor for Health Affairs at Vanderbilt Medical Center, noted that conducting endeavors such as this new partnership is precisely why the Meharry-Vanderbilt Alliance was formed. "I congratulate the hard work that has led to this collaboration and the quick results that the alliance has achieved," Jacobson said.

As a group, African-Americans face a disproportionate burden from cancer:

"This award will support a number of basic science and clinical initiatives," said Vanderbilt-Ingram Cancer Center Director Dr. Harold L. Moses, Benjamin F. Byrd Professor of Oncology. "We are pleased to have the opportunity to collaborate with Meharry to build a strong cancer program and to work together on clinical trials involving minority and other under-served groups. We also intend to collaborate with Meharry in a broader sense in the areas of prevention and outcomes-based research."

Among the specific activities that will be supported by the award:

A half-day oncology clinic, staffed by two Vanderbilt oncology fellows, has already been established at Metro-General, with plans to expand to two half-days each week, Moses said.

Dr. Clifton Meador, director of the Meharry-Vanderbilt Alliance, said that the cancer partnership will address at least two of the overall goals of the alliance - to move toward an integrated health delivery system between the two institutions and to increase participation by African-Americans in clinical trials of new treatments.

"Nationally, African-Americans are under-represented in clinical trials, not only in cancer but in other diseases as well," Meador said. "There are many factors involved in this disparity, including cultural and social barriers. We hope this partnership will help overcome some of these obstacles and make available some of the latest, most promising cancer treatments. We believe this will be a model for alliance initiatives in other areas."

The award from the NCI is a supplement to the Vanderbilt-Ingram Cancer Center's "cancer center core grant," which provides administrative support funding as part of its designation as a National Cancer Institute center. This designation, awarded to only 60 cancer centers throughout the country, recognizes excellence in cancer research, treatment and prevention. The Vanderbilt-Ingram Cancer Center is one of a select few NCI-designated cancer centers in the southeast and the only one in Tennessee dedicated to advancing research and patient care in all types of cancer in adults and children. Meharry Medical College is a private, historically black academic health center. Since its founding in 1876, Meharry has been a leading producer of African-American physicians and dentists, and today is one of the nation's leading providers of African-American doctorates in biomedical sciences. The College is known for its emphasis on the special primary health concerns of minorities, the poor and the disadvantaged.

Vanderbilt University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to